Traders should base analysis on the underlying index (XBI), as LABU's price action is distorted by leverage-induced drift.

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

Launched on February 5, 2001, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity ...

As the AI trade gets overheated and calls for some sort of bursting of the AI bubble grow louder, it might make sense to look ...

Biotech ETFs offer diversified exposure to multiple biotech stocks, reducing individual investment risk. Top biotech ETFs, like iShares and SPDR S&P, have large assets and low expense ratios.

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

Biotech ETFs have had a banner year, earning some investors returns north of 30 percent since January. I say “some investors” because, it turns out, not all biotech ETFs are created equal. In our 2012 ...

Launched on 06/23/2005, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market. What Are Smart Beta ...

XBI hits a 52-week high, climbing 85% from its low, as biotech gains momentum from AI adoption and favorable market trends.

This rally in Illumina proved a shot in the arm for one of the most Illumina-sensitive funds, the ARK Genomic Revolution ETF (BATS:ARKG). It surged about 4% this week to outperform broader biotech ...